Immune checkpoint inhibitor (ICI) combinations, as well as ICIs combined with tyrosine kinase inhibitors, have considerable potential for renal cell carcinoma (RCC) treatment. Newer targeted medications, gut microbiome, nanomedicines, and cyclin-dependent kinase (CDK) inhibitors demonstrate significant potential in preventing side effects and resistance associated with RCC treatment. Most patients, including those demonstrating long-term treatment effects, eventually demonstrate cancer progression. Nevertheless, recent studies have further revealed RCC pathogenesis and many acquired drug resistance mechanisms, which together have led to the identification of promising therapeutic targets. In addition to having roles in metabolism, immunogenicity, and the immune response to tumors, CDK4 and CDK6 regulate the cell cycle. Targeting CDK4 and CDK6, either separately or in combination with already approved treatments, may improve therapeutic outcomes in patients with kidney cancer. Other novel drugs, including pegylated interleukin 10, colony-stimulating factor 1 receptor inhibitors, CD40 agonists, and C-X-C receptor 4 inhibitors affect the tumor microenvironment and cancer cell metabolism. Moreover, a triple ICI combination has been noted to be efficacious. In general, compared with sunitinib as a single-drug treatment, newer ICI combinations improve overall survival in patients with RCC. Future research on the prevention of adverse events and medication resistance related to newer therapies may aid in ensuring effective treatment outcomes among patients with RCC. This article aims to summarize innovative immunotherapy drug combinations for RCC treatment and the mechanisms of action, drug resistance, and treatment of adverse events associated with these combinations.

Background: Congenital adrenal hyperplasia (CAH) is increasingly prevalent, leading to a surge in related research. To pinpoint emerging trends and recommend future directions, a bibliometric analysis of relevant CAH literature was performed. Methods: From January 1, 2000, to October 1, 2023, we searched the Web of Science Core Collection for CAH literature. For the bibliometric analysis, tools such as VOSviewer, CiteSpace, and the R package “bibliometrix” were employed. Results: The United States and England are at the forefront among 113 countries, contributing 5034 papers to CAH research. However, there is a need for more extensive global collaboration across institutions in this field. The number of publications on CAH is increasing annually. Leading research institutions include the University of Michigan, University of California, San Francisco, Karolinska Institutet, and Karolinska University Hospital. The Journal of Clinical Endocrinology & Metabolism is the most cited in this area. The most prolific author is Falhammar H, with 88 publications, 2568 co-citations, and a significant overall contribution. Key research areas include diagnostic methods and therapeutic strategies for CAH. Emerging research hotspots are identified by keywords such as “disorders of sex development,” “21-hydroxylase deficiency,” “ambiguous genitalia,” “testosterone” and “adrenal insufficiency.” Conclusions: Research on CAH is expected to expand globally. Future studies will primarily focus on exploring CAH’s diagnostic aspects and developing new therapies. This paper will help scholars better understand the dynamic evolution of the CAH and point out the direction for future research.

This study analyzed adverse drug events (ADEs) associated with basiliximab, sourced from the Food and Drug Administration Adverse Event Reporting System (FAERS) database, spanning the first quarter of 2004 to the fourth quarter of 2023. We collected ADE data for basiliximab from 2004 Q1 to 2023 Q4. After standardization, we employed several signal quantification methods for analysis, such as the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propensity for Neural Networks (BCPNN), and empirical bayes geometric mean (EBGM). In this analysis of 1520 ADEs reports citing basiliximab as the primary suspect, we identified 295 preferred terms across 24 system organ classifications (SOCs). The 3 most prevalent SOCs were investigated (n = 1403, ROR 2.84, PRR 2.54, IC 1.34, EBGM 2.54), infections and infestations (n = 1198, ROR 2.85, PRR 2.59, IC 1.37, EBGM 2.59), and renal and urinary disorders (n = 903, ROR 6.01, PRR 5.48, IC 2.45, EBGM 5.47). Increased blood creatinine and pyrexia were the most frequently reported adverse events (AEs) associated with basiliximab, and cytomegalovirus infection also demonstrated significant signal intensity. Notably, this study revealed some adverse reactions beyond basiliximab drug instructions, such as mitral valve calcification, diastolic dysfunction, pelvic fluid collection, testicular swelling, soft tissue necrosis, and muscle necrosis. Although basiliximab offers therapeutic benefits, it carries the risk of several adverse reactions. Clinicians should monitor patients for signs of increased serum creatinine level, fever, cytomegalovirus infection, anaphylactic shock, mitral valve calcification, diastolic dysfunction, pelvic fluid collection, testicular swelling, soft tissue necrosis, muscle necrosis, and other events during clinical use.

Oral cancer is among the most common malignant tumors of the head and neck. However, a comprehensive assessment of the burden of lip and oral cavity cancer (LOC) in adolescents and young adults (AYAs) aged 15 to 39 is still lacking. Using age- and sex-stratified data across global, regional, and national levels from 1990 to 2021, this study aimed to provide a comprehensive estimate of the burden of LOC in the AYAs population and analyzed global data on the incidence, mortality, and disability-adjusted life years (DALYs) linked to AYAs LOC from 1990 to 2021. Age-standardized rate and estimated annual percentage change, were used to assess AYAs LOC trends across gender, age, and socio-demographic index, as well as to evaluate disparities between countries. A Bayesian Age-Period-Cohort (BAPC) model was applied to forecast the disease burden from 2022 to 2041. In 2021, there were 29,223 cases of LOC globally (95% uncertainty interval [UI]: 24,871–33,190), resulting in 9815 deaths (95% UI: 8038–11,421) and 581,394 DALYs (95% UI: 474,111–677,536). At the regional, South Asia has the highest incidence, mortality, DALYs, and age-standardized rate by Global Burden of Disease classification. At the national, India had the highest numbers for incidence, deaths, and DALYs, while Palau recorded the highest age-standardized incidence rate, age-standardized mortality rate, and age-standardized disability-adjusted life year rate. The burden is most pronounced among AYAs aged 35 to 39. Among those aged 15 to 24, women experienced a greater burden than men, while in the 25 to 39 age group, men had a higher burden. Projections indicate that by 2041, the burden of LOC will continue to rise, with a greater impact on men than women. From 1990 to 2021, the global burden of LOC, when adjusted for age, has increased. However, regional variations have been observed, with the burden decreasing in some areas. Consequently, monitoring the condition of young patients with LOC is crucial for reducing this overall burden. Limitations remain in this study: data gaps in low-income countries affect the accuracy of the Global Burden of Disease, and the burden of LOC on AYAs was not stratified. Future work needs to improve data collection.

The dietary index for gut microbiota (DI-GM), which reflects microbiota diversity, has not yet been linked to lung cancer. To explore this, we analyzed the relationship between DI-GM and lung cancer using data from the National Health and Nutrition Examination Survey. This analysis used National Health and Nutrition Examination Survey data from 2007 to 2018. We assessed multicollinearity among the independent variables with variance inflation factors, then performed weighted logistic regression, subgroup analysis, and applied a restricted cubic spline model to explore the relationship between DI-GM and lung cancer. The study included 22,473 adults aged 20 and older. The adjusted findings indicated that a higher DI-GM was associated with a reduced likelihood of lung cancer. variance inflation factors confirmed the absence of multicollinearity. After adjusting for potential confounders, participants with the highest DI-GM had a 72% lower risk of developing lung cancer compared to those with the lowest scores (OR = 0.28; 95% CI: 0.09–0.84, P = .02). A linear negative correlation was observed between DI-GM and the risk of lung cancer. This cross-sectional investigation revealed a negative relationship between the DI-GM and the likelihood of lung cancer.

The link between benzodiazepines (BZs) use and lung cancer remains unclear. This paper investigates this association by analyzing data from 34,084 adults, aged approximately 47.08 ± 0.22 years, from the National Health and Nutrition Examination Survey study conducted between 2001 and 2016. Multiple logistic regression is employed to control for various factors including age, sex, ethnicity, education, poverty to income ratio, diabetes mellitus, smoke, alcohol user, hypertension, body mass index, hyperlipidemia, chronic obstructive pulmonary disease and other cancer, in order to explore the impact of BZs on lung cancer prevalence. The findings indicate that the risk of lung cancer is 4.643 times higher in BZs users compared to nonusers (95% CI: 2.096, 10.283), and this association remains significant (OR: 2.575, 95% CI: 1.015, 6.529) after adjusting for all variables. Our research indicates that among the American population, especially men aged 60 or above, with a normal weight BMI and no hypertension, the prevalence of lung cancer is relatively high among BZs users. This requires further research to verify these findings.